All news

Mesoblast posts US$28 million Ryoncil revenue

Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash

Mesoblast reported US$28 million in Ryoncil revenue for Q1 FY26, alongside an 85% improvement in net operating cash spend and a US$99 million cash balance. The company said the results strengthen the investment narrative for its cell therapy platform and its potential to scale. Ryoncil remains central to Mesoblast's strategy.

Read original source

MESO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.